Plasma adriamycin levels during remission induction therapy: RIA versus HPLC

Area of Science:

• Pharmacokinetics
• Oncology
• Analytical Chemistry

Background:

• Acute nonlymphocytic leukemia (ANLL) treatment often involves combination chemotherapy.
• Adriamycin (doxorubicin) and cytosine arabinoside (araC) are key agents in ANLL remission induction therapy.
• Accurate measurement of drug plasma concentrations is crucial for optimizing treatment and understanding toxicity.

Purpose of the Study:

• To compare plasma concentrations of adriamycin and its metabolite, adriamycinol.
• To evaluate the accuracy of high-performance liquid chromatography (HPLC) and radioimmunoassay (RIA) for quantifying these drugs.
• To assess drug levels during induction therapy for ANLL.

Main Methods:

• Patients with ANLL received induction therapy with araC and adriamycin.
• Blood samples were collected at multiple time points (10 min to 24 hrs) after adriamycin injections.
• Plasma concentrations were determined using both HPLC and a commercial RIA kit.

Main Results:

• A high degree of correlation was observed between adriamycin and adriamycinol plasma concentrations measured by HPLC and RIA.
• Correlation coefficients (r) ranged from 0.765 to 0.920 across different time points.
• A combined correlation coefficient of 0.853 for 57 samples was statistically significant (p = 0.005).

Conclusions:

• Both HPLC and RIA are reliable methods for measuring adriamycin and adriamycinol plasma levels in ANLL patients.
• These findings support the use of these analytical techniques in clinical settings to monitor chemotherapy.
• Accurate drug monitoring can aid in tailoring adriamycin dosage for improved therapeutic outcomes in leukemia treatment.